Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.

Yusuke TakahashiYuya SekoKanji YamaguchiKento TakeuchiKota YanoSeita KataokaMichihisa MoriguchiYoshito Itoh

Published in: Journal of gastroenterology and hepatology (2023)

Pemafibrate improves the FAST score of NAFLD patients with complicating dyslipidemia, especially in older patients with high GGT level. GGT is useful as an indicator of optimal treatment choice for NAFLD patients with dyslipidemia.

Keyphrases

physical activity
middle aged
liver fibrosis
decision making
combination therapy